Omada Health, Inc. (OMDA)
| Market Cap | 1.16B |
| Revenue (ttm) | 232.34M |
| Net Income (ttm) | -26.19M |
| Shares Out | 57.89M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365,046 |
| Open | 20.51 |
| Previous Close | 20.77 |
| Day's Range | 20.01 - 20.83 |
| 52-Week Range | 14.14 - 28.40 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.44 (+31.87%) |
| Earnings Date | Nov 6, 2025 |
About OMDA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy b... [Read more]
Financial Performance
In 2024, Omada Health's revenue was $169.80 million, an increase of 38.29% compared to the previous year's $122.78 million. Losses were -$47.14 million, -30.18% less than in 2023.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for OMDA stock is "Strong Buy." The 12-month stock price target is $26.44, which is an increase of 31.87% from the latest price.
News
Why Omada Health is finally prescribing Ozempic as TrumpRx slashes GLP-1 weight-loss drug costs
Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.
Omada Health, Inc. (OMDA) Q3 2025 Earnings Call Transcript
Omada Health, Inc. ( OMDA) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Allan Kells - Vice President of Investor Relations Sean Duffy - Co-Founder, CEO & Director Wei-Li Sh...
Omada Health Reports Third Quarter 2025 Results
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 202...
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. A...
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows
Virtual care company Omada Health said it will start prescribing GLP-1s and other obesity drugs and help patients manage those medications. The announcement expands the offerings under the company's w...
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the ...
Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical O...
Omada Health to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thur...
Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO...
Omada Health: Multiple Indicators Convince Me The Growth Outlook Remains Healthy
Omada Health (OMDA) remains a buy, driven by accelerating membership growth, multi-condition adoption, and a massive underpenetrated market opportunity. OMDA's GLP-1 Care Track is a standout product, ...
Omada Health, Inc. (OMDA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Omada Health, Inc. (NASDAQ:OMDA) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Sean Duffy - Co-Founder, CEO & Director Steven Cook - Chief...
New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions
SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada membe...
New Research from Omada Health Demonstrates Significant Cost Savings of Virtual Physical Therapy
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that patients who used Omada's virtual phy...
Omada Health to Participate in Upcoming Investor Conference
SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the M...
Omada Health beats on revenue in first earnings report since IPO
Omada Health reported quarterly results for the first time since its IPO in June. Omada's revenue increased 49% in its second quarter to $61 million.
Omada Health Reports Second Quarter 2025 Results
Revenue of $ 61 million, up 49% 52% Member Growth and Significant Progress Toward Profitability SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between...
Omada Health: Long Growth Runway Ahead
I rate Omada Health a buy due to its strong clinical validation, strategic partnerships, and vast untapped market opportunity. OMDA's clinical outcomes, backed by 29 peer-reviewed studies, provide a t...
Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thu...
Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program signi...
Omada Health: Helping Patients, Investors As Well?
Omada's IPO impresses with rapid revenue growth and a unique approach to chronic disease management, but the company remains unprofitable. Valuation is stretched at 5-6x sales, especially given contin...
Omada Health IPO signals healthier market, avoids ‘down-round' trend
The IPO market is starting to feel healthier.
Diabetes startup Omada Health finally went public after 14 years. Here's who made bank.
Omada Health just became the second digital health company to IPO this year. The chronic care company saw its shares jump Friday morning by over 38% above its initial price.
Omada Health IPO: CEO explains why the digital health company went public now
Telehealth provider Omada Health raised $150 million in its IPO as the company makes its public debut on the Nasdaq on Friday. Omada Health CEO Sean Duffy sits down with Yahoo Finance senior health re...
Digital health company Omada valued at $1.3 billion as shares jump in Nasdaq debut
Shares of Omada Health rose 21% in their Nasdaq debut on Friday, valuing the virtual chronic care provider at $1.28 billion.
Omada shares open at $23 in Nasdaq debut after health-tech company's IPO
Omada Health hit the Nasdaq on Friday after selling about $150 million worth of shares in its IPO. The company, which provides virtual chronic care, was valued at just over $1 billion in the offering.